What Does Lyell Immunopharma Do?

Total employees288
HeadquartersSouth San Francisco
FoundedN/A

Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors. The company focuses on advancing its proprietary ex vivo genetic and epigenetic reprogramming technologies, Gen-R and Epi-R, to address major barriers to successful adoptive T-cell therapy, primarily T-cell exhaustion and lack of durable stemness. Their pipeline includes product candidates targeting various solid tumor indications.

Where Is Lyell Immunopharma's Headquarters?

HQ Function

The headquarters serves as the central corporate office, housing executive leadership, core research and development laboratories, and essential administrative and operational functions.

Notable Features:

Features state-of-the-art research and development laboratories specifically designed for cutting-edge cell therapy innovation. The facility likely incorporates modern, collaborative workspaces conducive to scientific discovery, typical of leading biotech companies.

Work Culture:

Characterized by a fast-paced, science-driven, and highly collaborative environment. There is a strong emphasis on innovation, scientific rigor, and a patient-centric approach to developing transformative cancer therapies.

HQ Significance:

Its location in South San Francisco provides critical access to a rich ecosystem of talent, renowned research institutions, potential collaborators, and venture capital, vital for a clinical-stage biotech company.

Values Reflected in HQ: The headquarters reflects Lyell's commitment to innovation, scientific excellence, and collaboration through its investment in advanced research facilities and a design that fosters teamwork.

Location:

Lyell Immunopharma's primary operations, including research, corporate functions, and manufacturing, are based in the United States (California and Washington). While their therapies are being developed for global patient populations, their physical presence is currently concentrated in the U.S. Clinical trials for their product candidates may involve sites internationally, extending their operational reach in collaboration with research partners and clinical investigators worldwide.

Street Address:

201 Haskins Way

City:

South San Francisco

State/Province:

CA

Country:

USA

Where Else Does Lyell Immunopharma Operate Around the World?

Bothell, Washington, USA

Address: 11804 North Creek Parkway S, Bothell, WA 98011

Leverages the Seattle/Bothell region's established biotechnology sector and skilled workforce specializing in biomanufacturing and process development, supporting Lyell's clinical and future commercial supply needs.

Buying Intent Signals for Lyell Immunopharma

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Lyell Immunopharma? Meet the Executive Team

As of April 2025, Lyell Immunopharma' leadership includes:

Liz Homans - Chief Executive Officer
Charlie Newton - Chief Financial Officer
Gary Lee, Ph.D. - Chief Scientific Officer
Stephen Hill, M.D. - Chief Medical Officer
Heather Turner - Chief General Counsel and Corporate Secretary
Thérèse (“Tina”) M. Albertson, M.D., Ph.D. - Chief People and Technical Operations Officer

Who's Investing in Lyell Immunopharma?

Lyell Immunopharma has been backed by several prominent investors over the years, including:

ARCH Venture Partners
Foresite Capital
GSK plc
Altitude Life Science Ventures
Casdin Capital
GV (Google Ventures)
Verily
Funds and accounts advised by T. Rowe Price Associates, Inc.

What Leadership Changes Has Lyell Immunopharma Seen Recently?

Hire2
Exits0

Over the past 12 months (approx. mid-2023 to mid-2024), Lyell Immunopharma appointed Charlie Newton as Chief Financial Officer and promoted Thérèse (“Tina”) M. Albertson to Chief People and Technical Operations Officer. No C-suite executive departures were publicly announced during this period.

New Appointments:

Charlie Newton, Charlie Newton appointed as new Chief Financial Officer.
Thérèse (“Tina”) M. Albertson, M.D., Ph.D., Tina Albertson promoted to Chief People and Technical Operations Officer.

What Technology (Tech Stack) Is Used byLyell Immunopharma?

Discover the tools Lyell Immunopharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Lyell Immunopharma Email Formats and Examples

Lyell Immunopharma likely utilizes standard corporate email address formats. Common patterns include the first initial followed by the last name, or first name separated from the last name by a period.

flast@lyell.com (e.g., jdoe@lyell.com) or first.last@lyell.com (e.g., jane.doe@lyell.com)

Format

lhomans@lyell.com

Example

85%

Success rate

What's the Latest News About Lyell Immunopharma?

GlobeNewswireMay 7, 2024

Lyell Immunopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Lyell Immunopharma announced its financial results for the first quarter ended March 31, 2024, and provided updates on its clinical programs, LYL797 and LYL845, highlighting ongoing patient dosing and site activation for its Phase 1 trials in solid tumors....more

GlobeNewswireFebruary 27, 2024

Lyell Immunopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

The company reported its financial results for the fourth quarter and full year 2023, discussed advancements in its pipeline of T-cell therapies incorporating Gen-R and Epi-R technologies, and outlined key strategic priorities and anticipated milestones for 2024....more

GlobeNewswireNovember 3, 2023

Lyell Immunopharma Presents Initial Clinical Data from LYL797 Phase 1 Trial in Solid Tumors at the SITC 38th Annual Meeting

Lyell presented initial safety, cell product characterization, and correlative science data from its Phase 1 trial of LYL797, an ROR1-targeted CAR T-cell therapy enhanced with Gen-R and Epi-R, in patients with ROR1+ non-small cell lung cancer and triple-negative breast cancer....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Lyell Immunopharma, are just a search away.